Stock OBIO ORCHESTRA BIOMED HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Orchestra BioMed Holdings, Inc.

Equities

OBIO

US68572M1062

Market Closed - Nasdaq
Other stock markets
 21:00:00 17/05/2024 BST 		5-day change 1st Jan Change
5.27 USD +14.07% Intraday chart for Orchestra BioMed Holdings, Inc. +11.89% -42.28%
05-13 Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q1 Revenue $620,000 MT
05-13 Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
GL
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
GL
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
GL
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
AQ
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
GL
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
GL
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
GL
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
AQ
Orchestra BioMed to Participate in Upcoming Investor Conferences
GL
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
GL
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
GL
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years
AQ
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
AQ
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Orchestra BioMed to Present at Upcoming Investor Conferences
AQ
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients
GL
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update
GL
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis
GL
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes
GL
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OBIO Stock
  4. News Orchestra BioMed Holdings, Inc.
  5. Press Releases